MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical company developing and commercializing the candidates in its oncology-focused development pipeline. The Company’s lead product is aldoxorubicin, an improved formulation of the widely used chemotherapy agent, doxorubicin.
In company news, Seeking Alpha has published an article recapping the Company’s recent phase 2b clinical trial, a head-to-head clinical comparison of aldoxorubicin vs. doxorubicin in which aldoxorubicin demonstrated superiority as a first-line therapy for patients with soft tissue sarcoma.
The article, entitled “CytRx Corporation's Aldoxorubicin Looks Like A Winner,” can be found here: http://seekingalpha.com/instablog/15280302-u-s-biotech-investor/2523681-cytrx-corporations-aldoxorubicin-looks-like-a-winner.
“If trials continue as successfully as they have, Investors should see aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find an immediate market with a monstrous revenue stream,” writes U.S. Biotech Investor.
The article also highlights several supporting reasons the writer is bullish on CytRx stock, such as the Company’s financial position; option rights to the protein-binding platform technology that serves as the linker with doxorubicin; and key quotes from the Company’s CEO Steve Kriegsman.
For more information on CytRx Corp., visit http://www.MissionIR.com/CYTR.html
Released On: 4/8/2016
Views: 3784
Released On: 4/7/2016
Views: 4530
Released On: 3/31/2016
Views: 3502
Released On: 3/24/2016
Views: 2866
Released On: 3/17/2016
Views: 2414
Released On: 3/11/2016
Views: 2236
Released On: 3/4/2016
Views: 2556
Released On: 3/3/2016
Views: 2256
Released On: 2/23/2016
Views: 3603
Released On: 2/12/2016
Views: 2588
Released On: 2/10/2016
Views: 2306
Released On: 2/9/2016
Views: 2457
Released On: 1/20/2016
Views: 4248
Released On: 1/14/2016
Views: 4711
Released On: 1/5/2016
Views: 2960
Released On: 12/18/2015
Views: 9269
Released On: 12/9/2015
Views: 2712
Released On: 12/3/2015
Views: 3153